Added On July 5, 2020

 But bulk buying of this magnitude by the U.S. could mean that no other country will be able to purchase the medicine during this period.

The U.S. Department of Health and Human Services confirmed earlier this week that it had secured more than 500,000 treatment courses of Remdesivir from pharmaceutical giant Gilead Sciences, which is all of the company's production for July and 90 percent of that for August and September.
The U.S. move to buy up so much stock of the medicine has drawn criticism from other countries, including those who have participated in trials of Remdesivir.
The medicine was initially developed as a treatment against Ebola but failed to work as expected. So far it is the only drug that has an emergency use authorization from the U.S. Food and Drug Administration to treat COVID-19. 
Multiple Phase 3 studies are ongoing to determine the safety and efficacy of the drug for COVID-19 treatment.
Patients could pay as much as 3,120 U.S. dollars for a 5-day treatment course. Critics have slammed the pricing as "an outrage," given the amount taxpayers have invested in the drug's development.